US Pharma MarketingExecuting biomarker-driven oncology trials
Executing biomarker-driven oncology trials is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Why biomarker-driven oncology trials require new thinking across patient recruitment, assay development and regulatory strategy.
Source: FierceBiotech